[1] Lee YA,Wallace MC,Friedman SL. Pathobiology of liver fibrosis:a translational success story. Gut,2015,64（5）:830-841.
[2] Schuppan D,Kim YO. Evolving therapies for liver fibrosis. J Clin Invest,2013,123（5）:1887-1901.
[3] 许蓓,徐国光,郭清,等. 拉米夫定在重度肝纤维化慢乙肝患者中的长期应用疗效—NUCB4006十年随访研究. 中华传染病杂志,2010,28（11）:656-661.
[4] Marcellin P,Gane E,Buti M,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet,2013,381（9865）:468-475.
[5] 方玉才,王秋荚,潘统桧,等. 67例慢性丙型肝炎治疗过程及随访中血清ALT、病毒载量及肝纤维化指标的变化. 中华实验和临床病毒学杂志,2014,28（6）:461-463.
[6] 成军. 慢性丙型肝炎治疗的过去、现在和未来. 中国肝脏病杂志,2015,7（1）:4-5.
[7] Lam BP,Jeffers T,Younoszai Z,et al. The changing landscape of hepatitis C virus therapy:focus on interferon-free treatment. Therap Adv Gastroenterol,2015,8（5）:298-312.
[8] Arab JP,Candia R,Zapata R,et al. Management of nonalcoholic fatty liver disease:an evidence-based clinical practice review. World J Gastroenterol,2014,20（34）:12182-12201.
[9] Korean Association for the Study of the Liver. KASL clinical practice guidelines:management of alcoholic liver disease. Clin Mol Hepatol,2013,19（3）:216-254.
[10] Miranda-Mendez A,Lugo-Baruqui A,Armendariz-Borunda J. Molecular basis and current treatment for alcoholic liver disease. Int J Environ Res Public Health,2010,7（5）:1872-1888.
[11] Chang H,Xu A,Chen Z,et al. Long-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson's disease in children. Exp Ther Med,2013,5（4）: 1129-1132.
[12] 王美玲. 肝纤维化治疗研究进展. 实用肝脏病杂志,2013,16（4）:369-371.
[13] Casal Moura M,Liberal R,Cardoso H,et al. Management of autoimmune hepatitis:Focus on pharmacologic treatments beyond corticosteroids. World J Hepatol,2014,6（6）:410-418.
[14] Mata-Santos HA,Lino FG,Rocha CC,et al. Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis. Parasitol Res,2010,107（6）:1429-1434.
[15] Zhang Y,Li S,He L,et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis. Drug Des Devel Ther,2015,9:2757-2766.
[16] Kim MD,Kim SS,Cha HY,et al. Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis. Exp Mol Med,2014,46:e110.
[17] Mudaliar S,Henry RR,Sanyal AJ,et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology,2013,145（3）:574-582 e571.
[18] Dixon LJ,Berk M,Thapaliya S,et al. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest,2012,92（5）:713-723.
[19] Elpek GO. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis:An update. World J Gastroenterol,2014,20（23）:7260-7276.
[20] Nanthakumar CB, Hatley RJ,Lemma S,et al. Dissecting fibrosis:therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov,2015,14（10）:693-720.
[21] Marquardt D,Williams JA,Kucerka N,et al. Tocopherol activity correlates with its location in a membrane:a new perspective on the antioxidant vitamin E. J Am Chem Soc,2013,135（20）: 7523-7533.
[22] Sanyal AJ,Chalasani N,Kowdley KV,et al. Pioglitazone, vitamin E,or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,362（18）:1675-1685.
[23] Casas-Grajales S,Muriel P. Antioxidants in liver health. World J Gastrointest Pharmacol Ther,2015,6（3）:59-72.
[24] Jorgacevic B,Mladenovic D,Ninkovic M,et al. Rimonabant improves oxidative/nitrosative stress in mice with nonalcoholic fatty liver disease. Oxid Med Cell Longev,2015,2015: 842108.
[25] Mallat A,Teixeira-Clerc F,Lotersztajn S. Cannabinoid signaling and liver therapeutics. J Hepatol,2013,59（4）:891-896.
[26] Handy JA,Fu PP,Kumar P,et al. Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J,2011,440（3）:385-395.
[27] Lu N,Liu Y,Tang A,et al. Hepatocyte-specific ablation of PP2A catalytic subunit alpha attenuates liver fibrosis progression via TGF-beta1/Smad signaling. Biomed Res Int,2015,2015:794862.
[28] Qu Y,Zong L,Xu M,et al. Effects of 18alpha-glycyrrhizin on TGF-beta1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis. Int J Clin Exp Pathol,2015,8（2）:1292-1301.
[29] Liu C,Yuan X,Tao L,et al. Xia-yu-xue decoction （XYXD） reduces carbon tetrachloride （CCl4）-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-kappaB and TGF-beta1 signaling pathways. BMC Complement Altern Med,2015,15:201.
[30] Wang B,Li W,Chen Y,et al. Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis. Med Sci Monit,2012,18（10）:BR394-401.
[31] Shen M,Chen K,Lu J,et al. Protective effect of astaxanthin on liver fibrosis through modulation of TGF-beta1 expression and autophagy. Mediators Inflamm,2014,2014:954502.
[32] Granzow M,Schierwagen R,Klein S,et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology,2014,60（1）:334-348.
[33] Hong F,Chou H,Fiel MI,et al. Antifibrotic activity of sorafenib in experimental hepatic fibrosis:refinement of inhibitory targets, dosing,and window of efficacy in vivo. Dig Dis Sci,2013,58（1）:257-264.
[34] Kuo WL,Yu MC,Lee JF,et al. Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. J Gastrointest Surg,2012,16（2）:361-369.
[35] Choi SS,Sicklick JK,Ma Q,et al. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. Hepatology,2006,44（5）:1267-1277.
[36] Parsons CJ,Bradford BU,Pan CQ,et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology,2004,40（5）:1106-1115.
[37] Barry-Hamilton V,Spangler R,Marshall D,et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med,2010,16（9）:1009-1017.
[38] 李萍,杨秋辉,王俊岭,等. 吡菲尼酮对牛血清蛋白诱导的肝纤维化大鼠肝损害的保护作用观察. 实用肝脏病杂志,2015,18（1）:63-66.
[39] Salazar-Montes AM,Hernandez-Ortega LD,Lucano-Landeros MS,et al. New gene therapy strategies for hepatic fibrosis. World J Gastroenterol,2015,21（13）:3813-3825.
[40] 王寿明,何乐成,李鑫,等. 两种常用抗肝纤维化中成药临床疗效的比较. 肝脏,2014,19（5）:332-334.
[41] 李凌燕. 彩色多普勒超声评价安络化纤丸治疗慢性乙型肝炎的疗效研究. 中西医结合肝病杂志,2015,25（4）:236-238.
[42] 王堂明,邱波. 安络化纤丸对慢性乙型肝炎和肝硬化患者血清肝纤维化指标的影响. 实用肝脏病杂志,2005,8（1）:49-50.
[43] 靖旭,娄海燕,冯一民,等. 安络化纤丸对大鼠高脂性脂肪肝的治疗作用. 中国生化药物杂志,2012,33（6）:717-720.
[44] 相妍笑,娄海燕,王菊英,等. 安络化纤丸预防大鼠酒精性脂肪肝形成的作用. 中国生化药物杂志,2012,33（5）:537-543.
[45] 黄海燕,焦艾国,黄铁军,等. 安络化纤丸联合C-干扰素对血吸虫肝纤维化鼠T IMP-1及TGF-B1的影响. 中华医院感染学杂志,2009,19（1）:30-34.
[46] 张珊珊,李娅,徐峰. 熊去氧胆酸联合复方鳖甲软肝片治疗早中期原发性胆汁性肝硬化的临床疗效. 世界华人消化杂志,2015,23（26）:4251-4255. |
